– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

KORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint in the realm of large-volume subcutaneous infusion. The company announced a collaboration with a ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said a subcutaneous (under the skin) formulation of Tecentriq showed to be as good as an intravenous (IV) infusion of the drug in a study consisting of ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of10.3% over the forecast ...